Navigation Links
EAU launches new clinical guidelines for 2009 -- kidney cancer

Arnhem, The Netherlands A number of updated guidelines will be presented at the 24th Annual Congress of the European Association of Urology (EAU) held in Stockholm, from 17 though 21 March. The abridged versions - Pocket Guidelines which are based on the extended text documents will also be available in Stockholm to all EAU members and press.

Production of clinical guidelines is one of the core activities of the organisation. Close to 150 experts split up over 18 different topic-oriented panels, are involved in this ongoing process. Guidelines aim to present the best evidence available on a given pathology and provide a standardized approach to the treatment of urological conditions. Ultimately, healthcare professionals must make their own decisions about care on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge and expertise.

Kidney Cancer

Due to the enhanced use of imaging techniques over the past years a stage shift has been seen in the field of renal cell cancer with a volume increase in the incidental detection of smaller cancers (< 4 cm). Thirty percent of these findings are benign. The treatment of metastatic small tumours show a decrease in death rates. A considerable portion of these tumours can be treated with nephron sparing surgery. Additionally, a number of targeted agents have become available with several more expected shortly.

The panel updated these Kidney Cancer guidelines since for several targeted agents more mature data have been published and validated prognostic nomograms predicting treatment outcome accuracy are available for more treatment options.

The panel do not recommend Interferon-alpha (IFN-alpha) in a first-line setting as monotherapy in the treatment of metastatic RCC. Sunitinib and Bevacizumab + IFN-alpha are recommended as first-line therapy in low- and intermediate-risk patients while

Temsirolimus is recommended for high risk patients; Sorafenib and Everolimus can be recommended as second-line therapy after cytokine and tyrosine kinase inhibitor (TKI) failure, respectively.

The expectation is that further targeted agents will be on the market shortly. Also the role of molecular medicine in the treatment of renal cell carcinoma will become more prominent. A subsequent update will take this information in, once sufficiently data is available.

The panel consists of an expert group chaired by B. Ljungberg and includes D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard and I.C. Sinescu.


Contact: Lindy Brouwer
European Association of Urology

Related medicine news :

1. MIT scientist launches special nanoscience symposia at ACS National Meeting
2. ESA launches first Earth Explorer mission GOCE
3. HRSA Launches Online Resource to Help Prevent Poisonings
4., the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
5. Cardinal Health Launches New Products for the Operating Room
6. GeoFitness Launches Get Moving America Campaign to Improve Youth Health
7. Health Integrated Launches Unique Service for Health Plans Preparing for Federal Mental Health Parity Regulations
8. Confidential Listening Service We Just Listen Launches, Providing Americans a Private Platform to Express Their Thoughts and Feelings
9. eCardio Diagnostics Launches Academic Medicine Initiative
10. MorseLife Launches Learning Institute to Teach Best Practices in Leadership, Healthcare and Kosher Culinary
11. ADA Launches Community Dental Health Coordinator Program to Provide Dental Care in Underserved Areas
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: